1141 - 1150 of 8620 Results
Title
Year
- Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL‐AD preclinical testing core study2022OPENTitle: Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL‐AD preclinical testing core studyJournal Name: Alzheimer's & Dementia: Translational Research & Clinical InterventionsPublisher: WileyVol: 8Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/trc2.12329Best OA location URL: https://doi.org/10.1002/trc2.12329Citation Count: 16
-
OPENTitle: A Collaboration for Guiding the Rational Design of Multielement Solid CatalystsJournal Name: Angewandte Chemie International EditionPublisher: WileyVol: 62Issue #: 7Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/anie.202216327Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/anie.202216327Citation Count: 0
-
OPENTitle: A Collaboration for Guiding the Rational Design of Multielement Solid CatalystsJournal Name: Angewandte ChemiePublisher: WileyVol: 135Issue #: 7Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/ange.202216327Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ange.202216327Citation Count: 0
- Tracking cortical excitability dynamics with transcranial magnetic stimulation in focal epilepsy2022OPENTitle: Tracking cortical excitability dynamics with transcranial magnetic stimulation in focal epilepsyJournal Name: Annals of Clinical and Translational NeurologyPublisher: WileyVol: 9Issue #: 4Start Page: 540End Page: 551Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/acn3.51535Best OA location URL: https://doi.org/10.1002/acn3.51535Citation Count: 4
-
OPENTitle: Cognitive dysfunction 1 year after COVID‐19: evidence from eye trackingJournal Name: Annals of Clinical and Translational NeurologyPublisher: WileyVol: 9Issue #: 11Start Page: 1826End Page: 1831Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/acn3.51675Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acn3.51675Citation Count: 9
-
OPENTitle: Clinical trajectories and biomarkers for weight variability in early Parkinson’s diseaseJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 8Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41531-022-00362-3Best OA location URL: https://www.nature.com/articles/s41531-022-00362-3.pdfCitation Count: 15
-
OPENTitle: Plasma phosphorylated tau181 predicts cognitive and functional declineJournal Name: Annals of Clinical and Translational NeurologyPublisher: WileyVol: 10Issue #: 1Start Page: 18End Page: 31Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/acn3.51695Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acn3.51695Citation Count: 17
- Longitudinal corpus callosum microstructural decline in early-stage Parkinson’s disease in association with akinetic-rigid symptom severity2022OPENTitle: Longitudinal corpus callosum microstructural decline in early-stage Parkinson’s disease in association with akinetic-rigid symptom severityJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 8Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41531-022-00372-1Best OA location URL: https://www.nature.com/articles/s41531-022-00372-1.pdfCitation Count: 12
- Lipase regulation of cellular fatty acid homeostasis as a Parkinson’s disease therapeutic strategy2022OPENTitle: Lipase regulation of cellular fatty acid homeostasis as a Parkinson’s disease therapeutic strategyJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 8Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41531-022-00335-6Best OA location URL: https://www.nature.com/articles/s41531-022-00335-6.pdfCitation Count: 15
- Neuromelanin and T2*-MRI for the assessment of genetically at-risk, prodromal, and symptomatic Parkinson’s disease2022OPENTitle: Neuromelanin and T2*-MRI for the assessment of genetically at-risk, prodromal, and symptomatic Parkinson’s diseaseJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 8Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41531-022-00405-9Best OA location URL: https://www.nature.com/articles/s41531-022-00405-9.pdfCitation Count: 14